© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
DLBCL | Clinical
Not All Patients With Relapsed DLBCL Referred for CAR T in Community Setting
December 03, 2020
In an interview with Targeted Oncology, Ajeet Gajra, MD, FACP, vice president, Cardinal Health, discussed the ongoing challenges community oncologists face with prescribing CAR T-cell therapy to patients with relapsed/refractory diffuse large B-cell lymphoma.
Therapy Options Compared for the Treatment of Recurrent DLBCL
December 02, 2020
Loretta J. Nastoupil, MD, discussed the use of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma during a Targeted Oncology Case Based Peer Perspectives event.
Tafasitamab/Lenalidomide Combo Stands Out for Patients With Relapsed/Refractory DLBCL
December 01, 2020
During a Targeted Oncology Case Base Peer Perspective event, Ian W. Flinn, MD, PhD, compares the combination of tafasitamab-cxix plus lenalidomide, and selinexor as treatment of relapsed or refractory diffuse large B-cell lymphoma to other other available regimens.
In Patients With Relapsed/Refractory DLBCL, Tafasitamab/Lenalidomide Combo Shines
November 26, 2020
Kami J. Maddocks, MD, discussed the efficacy and safety of tafasitamab in combination with lenalidomide as treatment of a 74-year-old man with diffuse large B-cell lymphoma. The treatment option was discussed with a group of oncologists during a Targeted Oncology Case Based Peer Perspective event.
FDA Grants Priority Review to Lonca in R/R Diffuse Large B-Cell Lymphoma
November 20, 2020
The FDA has accepted a Biologic License Application for loncastuximab tesirine as treatment of relapsed or refractory diffuse large B-cell lymphoma and granted it a Priority Review designation.
CAR T-Cell Therapy Continues to Spark Interest for Treatment of Patients With DLBCL
November 18, 2020
In an interview with Targeted Oncology, Nilanjan Ghosh, MD, discussed the current challenges in using CAR T-cell therapy as treatment of patients with DLBCL and considers the next steps for this research.
Providing CAR T-Cell Therapy for Patients With DLBCL During COVID-19
November 18, 2020
Nilanjan Ghosh, MD, discusses the effect coronavirus disease 2019 had on using chimeric antigen receptor T-cell therapy to treat patients with diffuse large B-cell lymphoma.
Biomarker for Immune Response Identified in Relapsed/Refractory DLBCL
November 14, 2020
In patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), findings from the ongoing phase 2 SPiReL study demonstrated that certain gene expressions are associated with response to DPX-Survivac plus pembrolizumab and intermittent, low-dose cyclophosphamide.
Unanswered Questions Remain in DLBCL With Use of CAR T-Cell Therapies
November 05, 2020
In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.
Clinical Cases in Relapsed and Refractory DLBCL
October 28, 2020
Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.